Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 305 of 5804
-
New drug duo targets hard-to-treat breast cancer in early trial
Disease control Not yet recruitingThis is an open-label, Simon's optimal two-stage design, single-arm, Phase II study with first 6 patients in the safety run-in portion. PIK3CAmut advanced triple-negative breast cancer(TNBC) patients who have progressed on at least one prior line of systemic therapy in advanced s…
Phase: PHASE2 • Sponsor: Hu Hai • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
AI-Powered sperm selection could boost IVF success
Disease control Not yet recruitingThis study looks at an investigational automated, artificial intelligence (AI)-based sperm selection technology called the BAIBYS™ System. We want to see how it compares to current methods in terms of efficiency and effectiveness in producing high-quality Embryos, which can lead …
Phase: NA • Sponsor: BAIBYS Fertility • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Donor immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis is an investigator-initiated, single-arm, open-label, non-randomised phase I clinical study. The objective of this trial is to evaluate the safety, tolerability and pharmacokinetics of donor-derived CD19 CAR Therapy bridged Allo-HSCT and sequential donor-derived CD22 CAR The…
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy targets Hard-to-Treat breast cancer liver metastases
Disease control Not yet recruitingThis is a prospective, open-label, phase II platform trial. The purpose of this study is to test the safety and effectiveness of multi-mode thermal therapy combined with immunotherapy in patients with HER2-negative breast cancer with liver metastases who had previously received s…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail targets hard-to-treat lung cancer before surgery
Disease control Not yet recruitingThis study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib sequentially combined with ivonescimab and chemotherapy …
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Low-Dose radiation plus immunotherapy shows promise in rectal cancer trial
Disease control Recruiting nowThis is a prospective, open-label, randomized, parallel-group phase II trial evaluating the efficacy and safety of a low-dose radiotherapy sensitization strategy combined with a PD-1 antibody (pucotenlimab) and CAPEOX as neoadjuvant therapy in patients with pMMR/MSS locally advan…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising Three-Drug cocktail targets Hard-to-Treat leukemia
Disease control Not yet recruitingAcute myeloid leukemia Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual incidence rate of AML is 4.1 per 100000 people in the US and is higher in patients older than 6…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill shows promise for teens with rare brain cancer
Disease control Not yet recruitingThe objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric participants aged 12 to \< 18 years old with grade 2 glioma with an IDH1 or IDH2 mutation. The study includes a screening period…
Phase: PHASE2 • Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.) • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo aims to clear leukemia before transplant
Disease control Not yet recruitingTo study the minimal residual disease (MRD) clearance rate of olverembatinib combined with inotuzumab ozogamicin as first-line consolidation chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who have not achieved MRD remission af…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Tailored sleep apnea therapy shows promise for down syndrome
Disease control Recruiting nowDown syndrome is the most common genetic cause of intellectual disability. People with Down syndrome often have obstructive sleep apnea (OSA), a condition where people have difficulties with breathing while asleep. OSA can lead to poor sleep, worse quality of life, behavior probl…
Phase: PHASE4 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Steroid showdown: trial aims to perfect rejection treatment for kidney transplants
Disease control Recruiting nowAfter a kidney or a simultaneous kidney-pancreas transplant, some patients may face problems with their new organs. This happens because the body sometimes makes a mistake and tries to get rid of the organ. This problem is called rejection. One type of rejection is known as Acute…
Phase: PHASE3 • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug could help rare fat disorder patients
Disease control Recruiting nowThis study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also lo…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Cholesterol drug could boost cancer therapy in patients with specific gene mutation
Disease control Recruiting nowThe investigators hypothesize that simvastatin (SIM) may improve the efficacy of first- line Nivolumab and Oxaliplatin-based chemotherapy, extending progression-free survival (PFS) as compared with Nivolumab and chemotherapy alone in patients with HER2 negative and ARID1A mutated…
Phase: PHASE2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for kidney cancer patients whose disease returns after standard therapy
Disease control Recruiting nowThe study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 2…
Phase: PHASE2 • Sponsor: Karie Runcie • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug frexalimab aims to outperform tacrolimus in kidney transplants
Disease control Recruiting nowThe purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 …
Phase: PHASE2, PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill could help kidneys last longer
Disease control Recruiting nowThe study is a Phase III clinical trial to evaluate the superiority of HRS-1780 tablets compared with placebo in delaying renal function decline in participants with chronic kidney disease (CKD) on the basis of standard treatment.
Phase: PHASE3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New asthma drug aims to stop attacks before they start
Disease control Recruiting nowThe aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could early heart pump support save more lives in severe shock?
Disease control Recruiting nowVenoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used worldwide to treat severe cardiogenic shock. The survival rate of these patients has increased in the last decade, reaching 45-50% for patients with acute myocardial infarction (AMI), the most f…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New weekly shot aims to prevent bleeding in hemophilia patients
Disease control Recruiting nowThe purposes of this open-label, multicenter III clinical trial are to evaluate the safety and efficacy of long-term preventive treatment with KN057 in Haemophilia A or B patients with or without inhibitors, and to assess the pharmacokinetic characteristics of the new and old pro…
Phase: PHASE3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Neck surgery aims to drain Alzheimer's brain waste
Disease control Recruiting nowThis multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial is to evaluate the efficacy and safety of deep cervical lymphatic venous anastomosis (DC-LVA) plus usual care versus usual care in reduing the score of clinical dementia rating-sum of boxes (…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC